Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
Résumé
Highlights d AXL and c-MET are overexpressed in radiotherapy-and cisplatin-resistant HNSCC d Overexpression of AXL and c-MET contributes to tumor aggressiveness and poor prognosis d Cabozantinib has anti-tumor and anti-metastatic efficacy in mice and zebrafish models d Cabozantinib efficacy is shown on HNSCC biopsies and in one patient after several relapses
Domaines
Sciences du Vivant [q-bio]| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|